Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + camrelizumab
- Development stage
- Unknown
- Lead developer
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + camrelizumab is a combination therapy that pairs anlotinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic properties, and camrelizumab, a PD-1 inhibitor immunotherapy. This combination leverages dual mechanisms of action: anlotinib inhibits vascular endothelial growth factor receptors (VEGFRs) to normalize the tumor microenvironment and reduce tumor angiogenesis, while camrelizumab blocks the PD-1 pathway to enhance T-cell activity against tumor cells. The combination has demonstrated synergistic effects in various cancer types, with promising efficacy and manageable safety profiles.
- Brand names
- AiRuiKaFukewei
- Other names
- SHR-1210 + anlotinibcamrelizumab plus anlotinibSHR-1210 plus anlotinibSHR1210 plus anlotinibSHR 1210 plus anlotinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + camrelizumab.